Guide · GLP-1 telehealth
Released: · Last reviewed:
Each red flag below is tied to the FDA's own wording or a recent FDA warning letter, so you can check a program against the regulator's list.
The FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, lists seven telehealth red flags for online sellers, from prices "that seem too good to be true" to labels with wrong addresses, and reports 990 adverse events for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026 (page read October 15, 2026).
One red flag does not prove a program is unsafe, but each one is a reason to ask questions before you pay.
Below are eight red flags we check on every program, each tied to the FDA's own wording or to a recent FDA warning letter. Use them as a filter before you compare prices or features.
The biggest are claims that a compounded drug is the same as an FDA-approved one, no real screening, no clinician after delivery, unnamed pharmacies, and unusual ingredients. The FDA flags each of these on its consumer page, and its September and October 2026 warning letters show them happening in practice.
The FDA warns about a company that "makes claims such as the compounded drug is the same as an FDA-approved drug." Compounded tirzepatide and semaglutide are not FDA-approved and are not generics. A program that blurs this is misleading you about the one fact that matters most.
The FDA lists "prices that seem too good to be true." For context, compounded tirzepatide programs in our index publish $86–$399 a month and semaglutide $49–$299, as of October 15, 2026. A price well below those ranges, with no membership or prepay explaining it, deserves hard questions.
A seller that "does not require a screening and prescription by a licensed doctor" is on the FDA's list. If you can check out without answering questions about your history, medicines and eating patterns, nobody is screening you. See our note on eating-disorder screening.
The FDA also flags a company that "does not have a licensed doctor available to answer questions after you receive your medication." Dose increases and side effects happen weeks after sign-up. Ask how you reach a prescriber, and how fast.
The FDA lists labels with "spelling errors" or "incorrect addresses of the pharmacy," a pharmacy name "you think might be fraudulent," medicine that looks different from before, and packaging that is "broken or damaged or lacks instructions for use." A legitimate program names its pharmacy before you pay.
The FDA says these salt forms "are different active ingredients than are used in the approved drugs." If either appears on a label or product page, the brand trial evidence does not apply to what you are injecting.
On October 6, 2026 the FDA posted warning letters 737806 and 737810 to websites selling unapproved injectable semaglutide under other names. The FDA also states that "retatrutide and cagrilintide cannot be used in compounding under federal law." Any program offering them is outside the rules.
FDA warning letter 738238 to Empower Pharmacy, posted September 22, 2026, said its compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products," and cited insanitary conditions. Adding B12 or niacinamide does not turn a copy into something new.
| # | Red flag | FDA basis | What to check |
|---|---|---|---|
| 1 | "Same as" or "generic" claims | Consumer page, October 1, 2026 | Product page wording |
| 2 | Price far below the market | Consumer page | 12-month total vs our index range |
| 3 | No screening | Consumer page | Intake questions before checkout |
| 4 | No clinician after delivery | Consumer page | How you reach a prescriber |
| 5 | Unnamed pharmacy, label errors | Consumer page | Pharmacy name, city, state license |
| 6 | Sodium or acetate salt forms | Consumer page | Ingredient on label |
| 7 | Rebranded or non-compoundable drugs | Warning letters 737806, 737810; consumer page | Drug name, retatrutide or cagrilintide offers |
| 8 | Vitamin add-in "copies" | Warning letter 738238 (Empower) | Combination products |
No more than 28 days after first use. The FDA tells patients to "discard the vial within 28 days after the first use, even if medication remains in the vial." A program shipping a single vial meant to cover two or three months is setting you up to break that rule or waste medicine.
Yes, if it promises a specific amount of weight loss. Trial averages were 20.9% for tirzepatide 15 mg at 72 weeks (SURMOUNT-1, treatment-regimen estimand) and 14.9% for semaglutide 2.4 mg at 68 weeks (STEP-1), and many people lost less. A narrow, conditional refund on program fees is different, but read the conditions.
NexLife, 94/100 on our methodology v4.1, names three state-licensed 503A pharmacies on its plan pages and lists provider review through NexLife Medical Group. Its refund page offers program-fee refunds, not medication, if a member loses less than 5% of starting weight over six months, with conditions. Its plan pages also carry a banner promising more ("lose up to 10% in 6 months or get your money back") that does not match the policy page, so rely on the policy page.
It is not flawless. It is not the lowest standing price we track, since Eden Health and Mondae publish lower prices. Cancellation takes effect after 30 days, its pages do not state labs are included, and its multi-month billing wording is unclear. See the NexLife review and how we rank.